#1 Clinical Trials Search in Europe

Potassium Oxybate

This article discusses a clinical trial investigating the effects of switching narcolepsy patients from high-sodium oxybate to XYWAV, a mixed-salt formulation containing potassium oxybate. The study aims to evaluate changes in blood pressure and other related factors in participants with narcolepsy when transitioning to this new treatment option.

Table of Contents

What is Potassium Oxybate?

Potassium oxybate is a medication that belongs to a group of drugs known as central nervous system depressants. It is one of the active ingredients in a medication called XYWAV, which is a mixed-salt formulation of oxybate[1]. XYWAV contains a combination of sodium oxybate, calcium oxybate, magnesium oxybate, and potassium oxybate.

Medical Uses

The primary medical use of potassium oxybate, as part of the XYWAV formulation, is for the treatment of narcolepsy. Narcolepsy is a chronic sleep disorder characterized by overwhelming daytime drowsiness and sudden attacks of sleep[1]. There are two types of narcolepsy:

  • Type 1 Narcolepsy: This type is characterized by sudden loss of muscle tone (cataplexy) and low levels of a brain hormone called hypocretin.
  • Type 2 Narcolepsy: This type does not involve cataplexy.

Both types of narcolepsy can be treated with XYWAV, which contains potassium oxybate[1].

Formulation and Administration

XYWAV, which contains potassium oxybate, is formulated as an oral solution. This means it’s a liquid medication that is taken by mouth. The medication is typically administered twice nightly[1]. The maximum daily dose is usually 9 grams, divided into two doses.

Clinical Trial Overview

A clinical trial is being conducted to evaluate the effects of switching patients from a high-sodium oxybate formulation to XYWAV (which includes potassium oxybate). The main focus of this study is to assess changes in blood pressure in narcolepsy patients[1].

The primary objective of the trial is to evaluate the impact of this switch on 24-hour ambulatory systolic blood pressure (SBP). Systolic blood pressure is the pressure in your arteries when your heart beats[1].

Eligibility Criteria

To participate in this clinical trial, patients must meet certain criteria, including:

  • Age between 18 and 70 years
  • Diagnosed with Type 1 or Type 2 narcolepsy
  • Currently taking a high-sodium oxybate medication
  • Have specific blood pressure readings

There are also several exclusion criteria, such as certain medical conditions or medications that would prevent participation[1].

Potential Benefits

The potential benefit of switching to XYWAV (containing potassium oxybate) from a high-sodium oxybate formulation is the possibility of improved blood pressure control. High sodium intake is associated with increased blood pressure, so reducing sodium while maintaining the therapeutic effects of oxybate could be beneficial for some patients[1].

Precautions and Considerations

While potassium oxybate (as part of XYWAV) can be an effective treatment for narcolepsy, there are several important considerations:

  • Medical History: Patients with certain cardiovascular conditions, kidney problems, or a history of substance abuse may not be suitable candidates for this medication[1].
  • Pregnancy and Breastfeeding: Special considerations apply for women who are pregnant, breastfeeding, or of childbearing potential[1].
  • Drug Interactions: XYWAV may interact with other medications, particularly those that affect blood pressure or the central nervous system[1].
  • Side Effects: As with any medication, there may be side effects. These should be discussed with a healthcare provider.

It’s crucial to note that potassium oxybate should only be taken under the close supervision of a healthcare provider. Never adjust your dosage or stop taking the medication without consulting your doctor first.

Aspect Details
Study Type Open-label, multicenter switch study
Main Objective Evaluate blood pressure changes when switching from high-sodium oxybate to XYWAV
Participants Adults (18-70 years) with Type 1 or Type 2 narcolepsy
Intervention Switch from high-sodium oxybate to XYWAV (potassium oxybate-based mixed-salt formulation)
Primary Endpoint Change in 24-hour average systolic blood pressure
Secondary Endpoints Changes in daytime, nighttime, and seated resting systolic blood pressure
Study Duration Up to 6 weeks
Key Inclusion Criteria Narcolepsy diagnosis, current use of high-sodium oxybate, specific blood pressure range
Key Exclusion Criteria Unstable medical conditions, significant cardiovascular disease, substance use disorders

FAQ

  • What is the main purpose of this clinical trial? The main purpose is to evaluate how switching from high-sodium oxybate to XYWAV affects 24-hour ambulatory systolic blood pressure in narcolepsy patients.
  • Who can participate in this study? Participants must be 18 to 70 years old, have a documented diagnosis of Type 1 or Type 2 narcolepsy, and have been taking high-sodium oxybate at a specific dose for at least 6 weeks prior to screening.
  • What is XYWAV? XYWAV is a mixed-salt formulation containing potassium oxybate, sodium oxybate, calcium oxybate, and magnesium oxybate. It is being studied as an alternative to high-sodium oxybate for narcolepsy treatment.
  • How long does the study last? The study lasts up to 6 weeks, during which participants will switch from their current high-sodium oxybate treatment to XYWAV.
  • What are the main measurements taken during the study? The study primarily measures changes in 24-hour average systolic blood pressure. It also looks at daytime, nighttime, and seated resting blood pressure changes.

Ongoing Clinical Trials on Potassium Oxybate

  • Study on Blood Pressure Changes in Narcolepsy Patients Switching from High-Sodium Oxybate to JZP258 (Oxybate Mixed-Salt Formulation)

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia France Italy Spain

Glossary

  • Narcolepsy: A chronic sleep disorder characterized by excessive daytime sleepiness and sudden attacks of sleep.
  • Systolic Blood Pressure (SBP): The pressure in your arteries when your heart beats, typically the higher number in a blood pressure reading.
  • Diastolic Blood Pressure (DBP): The pressure in your arteries when your heart is at rest between beats, typically the lower number in a blood pressure reading.
  • Ambulatory Blood Pressure: Blood pressure measurements taken at regular intervals throughout the day and night, usually with a portable device.
  • XYWAV: A mixed-salt formulation containing potassium oxybate, sodium oxybate, calcium oxybate, and magnesium oxybate, used to treat narcolepsy.
  • High-sodium oxybate: A medication used to treat narcolepsy that contains a high amount of sodium.
  • ICSD-3: International Classification of Sleep Disorders, 3rd edition, a diagnostic manual for sleep disorders.
  • DSM-5: Diagnostic and Statistical Manual of Mental Disorders, 5th edition, used for diagnosing mental health conditions.
  • Creatinine clearance: A test that measures how well your kidneys are working by estimating how much blood the kidneys can filter in a minute.
  • Phenylketonuria: A rare genetic disorder that causes an amino acid called phenylalanine to build up in the body.

References

  1. http://clinicaltrials.eu/trial/study-on-blood-pressure-changes-in-narcolepsy-patients-switching-from-high-sodium-oxybate-to-jzp258-oxybate-mixed-salt-formulation/